

08/30/2007 12:02 FAX

WILMER CUTLER PICK

RECEIVED
CENTRAL FAX CENTER 001/003

AUG 30 2007

WILMERHALE 

FACSIMILE

Date August 30, 2007

(1)
(1)

To Thuy Nguyen
USPTO

Fax 571-273-0824
Tel 571-272-0824

cc

From Jane M. Love, Ph.D. *JML*

Pages 3 (including cover)

Re

Please see attached.

Wilmer Cutler Pickering Hale and Dorr LLP, 399 Park Avenue, New York, New York 10022

Baltimore Beijing Berlin Boston Brussels London New York Oxford Palo Alto Waltham Washington

This facsimile transmission is confidential and may be privileged. If you are not the intended recipient, please immediately call the sender or, if the sender is not available, call +1 212 230 8800 and destroy all copies of this transmission. If the transmission is incomplete or illegible, please call the sender or, if the sender is not available, call +1 212 230 8800. Thank you.

RECEIVED
CENTRAL FAX CENTER

AUG 30 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Serial No. : 10/022,631
Applicant : Maurits W. Geerlings
Filed : December 17, 2001
Group Art Unit : 1641
Examiner : Thuy Nguyen
Docket No. : 1000780-120-US1
Customer No. : 28089

Title : METHOD AND MEANS FOR SITE-DIRECTED THERAPY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Terminal Disclaimer

Actinium Pharmaceuticals, Inc. ("Actinium"), the assignee of record of the entire right, title and interest of the subject application by virtue of an Assignment of that was recorded in the United States Patent and Trademark Office on January 22, 2002 at Reel 012548, Frame 0739 from the inventor of the parent application (USSN 09/014,206, now USPN 6,403,771) of the above-identified application, hereby disclaims, except as provided below, the terminal portion of the statutory term of any patent granted on the above-identified patent application, U.S. Serial No. 10/022,631, which would extend beyond the earliest expiration date of the full statutory term defined in 35 U.S.C. §154 to §156 and §173 of U.S. Patent No. 5,641,471 and U.S. Patent No. 6,403,771, and hereby agrees that any patent granted on the subject application shall be enforceable only for and during such period that the legal title to such patent shall be the same as the legal title to the aforementioned patents, this agreement to run with any patent granted on the subject application and to be binding upon the grantee, its successors and assigns.

In making the above disclaimer, Actinium does not disclaim the terminal part of any patent granted on the subject application that would extend to the expiration date of U.S. Patent No. 5,641,471 and U.S. Patent No. 6,403,771 the full statutory term as defined in 35 U.S.C. §154 to §156 and §173 of in the event that such prior patent later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321, has all claims

Page 1 of 2

USIDOC5 6342433v1


canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

I have reviewed the assignment attached hereto and certify that to the best of my knowledge and belief, Actinium, has the entire right, title and interest in the subject application. I further certify that I am authorized to sign this Terminal Disclaimer on behalf of Actinium.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: August 29, 2007

Actinium Pharmaceuticals, Inc.

By: 

Richard Sherman, Esq.
General Counsel
Actinium Pharmaceuticals, Inc.